There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Strongbridge Biopharma (SBBP) and Xenetic Biosciences (XBIO) with bullish sentiments.
Strongbridge Biopharma (SBBP)
In a report issued on January 6, Hartaj Singh from Oppenheimer maintained a Buy rating on Strongbridge Biopharma. The company’s shares closed last Tuesday at $3.09.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 15.5% and a 48.1% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Strongbridge Biopharma is a Strong Buy with an average price target of $8.67, which is a 180.6% upside from current levels. In a report issued on January 7, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
See today’s analyst top recommended stocks >>
Xenetic Biosciences (XBIO)
In a report issued on December 20, Ladenburg Thalmann from Ladenburg Thalmann & Co. initiated coverage with a Buy rating on Xenetic Biosciences and a price target of $10.00. The company’s shares closed last Tuesday at $2.57.
Currently, the analyst consensus on Xenetic Biosciences is a Moderate Buy with an average price target of $3.75, implying a 33.0% upside from current levels. In a report issued on January 8, Maxim Group also initiated coverage with a Buy rating on the stock with a $2.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
